Your browser version may not work well with NCBI's Web applications. More information here...
1: J Clin Child Psychol. 2001 Mar;30(1):80-7.Links
Comment in:
J Clin Child Psychol. 2001 Mar;30(1):110-3.

Pharmacological interventions in autism: theoretical and practical issues.

Volkmar FR.

Child Study Center, Yale University, P.O. Box 207900, New Haven, CT 06520, USA. fred.volkmar@yale.edu

Focused on issues of drug treatment in relation to autism. Pharmacological treatment studies in autism are complicated by various factors including a tremendous range of syndrome expression, a lack of robust animal models of the disorder, and various methodological problems. Theories have tended to follow treatments, and various neurochemical systems have been the focus of study. Neurochemical systems potentially implicated include those involving dopamine, norepinephrine, serotonin, and neuropeptides. The dopaminergic system has been the most extensively studied. Treatments developed are effective relative to certain disabling symptoms but "core" problems (e.g., in social relatedness and communication) appear less responsive to medications. The development of new approaches to assessment, including integration of behavioral and pharmacological approaches, is an important research priority.

PMID: 11294081 [PubMed - indexed for MEDLINE]